Skip to content
10-Q

Quarterly Report

CELLULAR BIOMEDICINE GROUP, INC.

0001654954-20-004977

← back to feed
Filed
May 6, 2020 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2020 · May 4, 2020 19.39M sh
Shares Diluted Q1 2020 · Mar 31, 2020 19.34M sh
Shares Diluted Q1 2020 · Mar 31, 2019 18.15M sh
Capex Q1 2020 · Mar 31, 2020 $1.58M
Capex Q1 2020 · Mar 31, 2019 $3.55M
Operating Cash Flow Q1 2020 · Mar 31, 2020 −$9.29M
Operating Cash Flow restated Q1 2020 · Mar 31, 2019 −$7.94M
Short Term Debt Q1 2020 · Mar 31, 2020 $14M
Short Term Debt Q1 2020 · Dec 31, 2019 $14.33M
Stockholders Equity Q1 2020 · Mar 31, 2020 $45.15M
Stockholders Equity Q1 2020 · Dec 31, 2019 $55.72M
Stockholders Equity Q1 2020 · Mar 31, 2019 $92.51M
Stockholders Equity Q1 2020 · Dec 31, 2018 $85.22M
Current Liabilities Q1 2020 · Mar 31, 2020 $23.53M
Current Liabilities Q1 2020 · Dec 31, 2019 $23.67M
Total Liabilities Q1 2020 · Mar 31, 2020 $40.74M
Total Liabilities Q1 2020 · Dec 31, 2019 $41.61M
Current Assets Q1 2020 · Mar 31, 2020 $23.56M
Current Assets Q1 2020 · Dec 31, 2019 $34.03M
Total Assets Q1 2020 · Mar 31, 2020 $85.89M
Total Assets Q1 2020 · Dec 31, 2019 $97.32M
Sga Expense Q1 2020 · Mar 31, 2020 $3.43M
Sga Expense Q1 2020 · Mar 31, 2019 $3.45M
Rd Expense Q1 2020 · Mar 31, 2020 $7.76M
Rd Expense Q1 2020 · Mar 31, 2019 $5.97M
Net Income Q1 2020 · Mar 31, 2020 −$11.55M
Net Income Q1 2020 · Mar 31, 2019 −$9.34M
Operating Income Q1 2020 · Mar 31, 2020 −$11.43M
Operating Income Q1 2020 · Mar 31, 2019 −$9.42M
Cost Of Revenue Q1 2020 · Mar 31, 2020 $0
Cost Of Revenue Q1 2020 · Mar 31, 2019 $8.09K
Revenue Q1 2020 · Mar 31, 2020 $0
Revenue Q1 2020 · Mar 31, 2019 $49.27K